Ian Haydock on Muck Rack

Ian Haydock

Verified
Tokyo
As seen in: Scrip, The Pink Sheet, Citeline, Generics Bulletin, HBW Insight, In Vivo, Medtech Insight, BioSpectrum Asia, AIS Health, European Pharmaceutical Manufacturer
Tokyo-based Editor-in-Chief, Asia-Pacific, for @PharmaScrip @PharmaPinkSheet, @citeline, @NorstellaCo. All views my own, RTs not endorsements.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ian

Contact Ian, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Ian Haydock’s Biography

Read Full Bio →

Ian is based in Tokyo and covers the Asian pharma markets for Scrip and its sister publication PharmAsia News (www.pharmasianews.com), of which he is managing editor. He writes about a broad range of business strategy and development, policy/regulatory and R&D issues relevant to both big pharma and smaller start-up firms, and has a particular interest in regulatory convergence initiatives in Asia. Ian has also covered of the Australian bioventure sector and aims to provide an analytical angle o…

Articles

Quick Listen: Scrip’s Five Must-Know Things

|
By Ian Haydock Verified
| Scrip Verified
Join us for an audio catch-up on the major events in the global biopharma industry over the past week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things. This episode covers insights for the business week ended June 19, 2026. This time—Pfizer lays out oncology direction; key topics at BIO 2026; GLP-1 access causes problems for obesity studies; GLP-1 use insights from Brazil; and Q1’s top 10 drugs.
Open in Who Shared Issue with article?

Weber Transformed Takeda - At A Cost

|
By Ian Haydock Verified, Lisa Takagi Verified
| Citeline Verified
Shire Acquisition And Beyond As Christophe Weber prepares to step down as CEO of Takeda this week after 11 years, Scrip takes a look back at his time at the helm, how the company has transformed, and successor Julie Kim's initial priorities. Julie Kim poised to succeed Christophe Weber as Takeda CEO (Takeda Pharmaceutical) When Christophe Weber became president and CEO of Takeda Pharmaceutical on Apr.
Open in Who Shared View Duplicates (2) Issue with article?

Asia Deal Watch: LG Chem Calls On LabGenius’s AI Capabilities For Multispecific Antibodies

|
By Joseph Haas Verified, Ian Haydock Verified, Xu Hu, Lisa Takagi Verified
| Scrip Verified
Plus deals involving JCR/Acumen, Everest/Dimerix, Dr. Reddy’s/Innoviva, Harbour Biomed/BioMap, Laekna/Vasque, WestGene/Cartesian and more. • Source: Alamy Other recent Asia deal coverage in Scrip: Conditions Are Right For Continued Heavy M&A Activity, PwC Says Everest On Licensing Spree After Investors Raise Stakes Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker.
Open in Who Shared Issue with article?
See all 1,116 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified